Tianlong Helps Hospitals in Thailand Detect Hepatitis Early with Molecular Diagnostic Solution

Summation

  • Tianlong, an innovative high-tech company specializing in molecular diagnostic products in China, has partnered with public hospitals in northern Thailand to build up detection measures for hepatitis C (HCV) and hepatitis B (HBV), and for the early diagnosis and treatment of the viruses.
  • The company has reached a 7-year agreement with local hospitals, and its solution will be seen in more local hospitals in the future.
  • The company believes that its molecular diagnostic solutions for hepatitis and other diseases will become increasingly popular in the local market, helping to improve the health and well-being of local people.

Tianlong, an innovative high-tech company specializing in molecular diagnostic products in China, has partnered with public hospitals in northern Thailand to build up detection measures for hepatitis C (HCV) and hepatitis B (HBV), and for the early diagnosis and treatment of the viruses. Globally, more than 350 million people are living with viral hepatitis, and 9 in ten people living with hepatitis are unaware of their diagnosis. Tianlong’s HCV&HBV detection solution can help reduce the transmission of the disease by enabling early diagnosis and proper treatment.

Since October 2022, Tianlong’s HCV&HBV detection solution has been successfully installed in public hospitals in Thailand. The company has reached a 7-year agreement with local hospitals, and its solution will be seen in more local hospitals in the future. Tianlong’s HCV&HBV reagents, compatible with its nucleic acid extractor PANA9600S and PCR system Gentier 96, provide a rapid test with high sensitivity, which has received great praise from high-end users.

Tianlong can give timely responses both online and offline when we need technical support. We have great confidence in Tianlong’s products, and we would welcome more cooperation in the future,” said a local hospital representative in Thailand.

Tianlong’s STIs solutions will also be applied in Thailand soon to help prevent and control sexually transmitted infections (STIs).

Tianlong is committed to expanding its presence in Thailand and working closely with local partners to provide excellent solutions and services for its customers. The company believes that its molecular diagnostic solutions for hepatitis and other diseases will become increasingly popular in the local market, helping to improve the health and well-being of local people.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Northwell Cardiothoracic Programs Have Nation’s Highest Success Rates

5 Northwell Cardiothoracic Programs (Northwell) include: Long Island Jewish Hospital, Lenox Hill Hospital, South Shore University Hospital, Staten Island University Hospital and the Sandra Atlas Bass Heart Hospital at North Shore University Hospital – received three-star ratings in their respective fields – the highest quality rating possible.

COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™

“AI has the potential to augment human learning and improve the accuracy and precision of cancer diagnostics and treatments,” said Dr. C.K. Wang, chief medical officer, COTA. “It is critical that we evaluate these tools against the current standard of care to validate their efficacy and build trust in AI and new technologies.”

AscellaHealth CEO, Dea Belazi, Honored as a 2024 PM360 Elite 100 Winner

Dea Belazi said, "This honor truly belongs to the entire AscellaHealth team in recognition of their expertise, dedication and ongoing work that enables patients with complex, chronic conditions to access specialty pharmaceuticals and novel therapies that enhance clinical outcomes."

By using this website you agree to accept Medical Device News Magazine Privacy Policy